Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal Cancer Research from the...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Submission for traditional approval follows FDA accelerated approval of LEQEMBI on the same day, and is based on data from the confirmatory Phase 3 Clarity AD clinical trial TOKYO and CAMBRIDGE, Mass.

Based on hhc (human health care) concept, our corporate philosophy, Eisai is committed to improve patients health outcomes and quality of life, simplify care delivery, increase health system...

LEQEMBI™ (lecanemab-rimb) has the potential to make a difference for people living with early Alzheimer's disease (AD), their loved ones and healthcare professionals, and was recently approved...

Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI™ Treatment with LEQEMBI should be initiated in patients with...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to transfer the United States (U.S.) commercial rights for the...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research...

Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN®, "eribulin") will be presented during the 2022 San Antonio...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will have a total of 34 posters, including the latest data on its in-house discovered and...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker findings from the company's Phase 3 confirmatory Clarity AD clinical trial for...

Data Include Provider-Reported Best Overall Response (BOR), Progression-Free Survival and Overall Survival in U.S. Patients NUTLEY, N.J., Oct. 21, 2022 /PRNewswire/ -- Eisai today announced final...

ALL KEY SECONDARY ENDPOINTS ALSO MET, DEMONSTRATING HIGHLY STATISTICALLY SIGNIFICANT RESULTS PROFILE OF AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA) INCIDENCE WAS WITHIN EXPECTATIONS EISAI AIMS TO...

RAHWAY, N.J. and NUTLEY, N.J., Sept. 10, 2022 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the...

Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Studies (Presentation: #259P) NUTLEY, N.J., Sept. 10, 2022 /PRNewswire/ -- Eisai announced today results...

Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular...

C2N Diagnostics and Eisai Inc. today announced the Companies have entered into a memorandum of understanding that will seek to build awareness about how blood-based assays for cognitive...

State-of-the-art Eisai US hhceco Center underscores New Jersey as the premier life science hub NUTLEY, N.J., Aug. 18, 2022 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai...

Campaign Provides Educational Resources on Liver Cancer and Encourages People to Make Some Daily Adjustments to Help Support Liver Health NUTLEY, N.J., Aug. 4, 2022 /PRNewswire/ -- Baseball legend...